Biology of Blood and Marrow Transplantation
Volume 16, Issue 2 , Pages 157-168 , February 2010

Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome

  • Jason A. Coppell

      Affiliations

    • Department of Haematology, Royal Devon and Exeter Hospital, Exeter, UK
    • The first two authors contributed equally to this manuscript.
    • Corresponding Author InformationCorrespondence and reprint requests: Jason A. Coppell, MA, MRCP, FRCPath, Haematology Centre, Level 1 Area B, Royal Devon and Exeter Hospital, Barrack Road, Exeter, Devon, UK, EX2 5DW.
    • ,
  • Paul G. Richardson

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • The first two authors contributed equally to this manuscript.
    • Corresponding Author InformationPaul G. Richardson, MD, FRCP, Division of Hematologic Malignancy, Dana-Farber Cancer Institute, Harvard Medical School, D1B30, 44 Binney Street, Boston, MA 02115.
    • ,
  • Robert Soiffer

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Paul L. Martin

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • Nancy A. Kernan

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Allen Chen

      Affiliations

    • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
    • ,
  • Eva Guinan

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Georgia Vogelsang

      Affiliations

    • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
    • ,
  • Amrita Krishnan

      Affiliations

    • City of Hope Cancer Center, Duarte, California
    • ,
  • Sergio Giralt

      Affiliations

    • Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Carolyn Revta

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Nicole A. Carreau

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Massimo Iacobelli

      Affiliations

    • Gentium SpA, Villa Guardia, Italy
    • ,
  • Enric Carreras

      Affiliations

    • Hospital Clinic, Barcelona, Spain
    • ,
  • Tapani Ruutu

      Affiliations

    • Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Tiziano Barbui

      Affiliations

    • Ospedali Riuniti, Bergamo, Italy
    • ,
  • Joseph H. Antin

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Dietger Niederwieser

      Affiliations

    • University of Leipzig, Leipzig, Germany

Received 2 March 2009 ,Accepted 21 August 2009.

References 

  1. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85:3005–3020
  2. Carreras E, Bertz H, Arcese W, et al. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. Blood. 1998;92:3599–3604
  3. Richardson P, Guinan E. The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol. 1999;107:485–493
  4. McDonald GB, Sharma P, Matthews DE, et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116–122
  5. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–267
  6. Jones RJ, Lee KS, Beschorner WE, et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778–783
  7. Bearman SI, Anderson GL, Mori M, et al. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol. 1993;11:1729–1736
  8. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation: immunohistochemical identification of the material within occluded central venules. Am J Pathol. 1987;127:549–558
  9. Shulman HM, Fisher LB, Schoch HG, et al. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology. 1994;19:1171–1181
  10. Kumar S, DeLeve LD, Kamath PS, et al. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc. 2003;78:589–598
  11. Bearman SI. Avoiding hepatic veno-occlusive disease: what do we know and where are we going?. Bone Marrow Transplant. 2001;27:1113–1120
  12. Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev. 2003;17:63–70
  13. Jacobs P, Miller JL, Uys CJ, et al. Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia. S Afr Med J. 1979;55:5–10
  14. Berk PD, Popper H, Krueger GR, et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation: possible association with graft-versus-host disease. Ann Intern Med. 1979;90:158–164
  15. Wadleigh M, Ho V, Momtaz P, et al. Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. Curr Opin Hematol. 2003;10:451–462
  16. Reiss U, Cowan M, McMillan A, et al. Hepatic veno-occlusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol. 2002;24:746–750
  17. Vogelsang GB, Dalal J. Hepatic veno-occlusive disease in blood and bone marrow transplantation in children: incidence, risk factors, and outcome. J Pediatr Hematol Oncol. 2002;24:706–709
  18. Chalandon Y, Roosnek E, Mermillod B, et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2004;10:347–354
  19. Richardson P, Kernan N, Tomblyn M, et al. A phase 3 randomized, historically controlled clinical trial investigating the use of defibrotide in the treatment of severe veno-occlusive disease post-SCT: a novel approach to the validation of a promising new drug for the treatment of a life-threatening disease. ASH Annual Meeting Abstracts. Blood. 2007;110:614
  20. Richardson P, Soiffer RJ, Antin JH, et al. Defibrotide (DF) for the treatment of severe veno-occlusive disease (sVOD) and multi-organ failure (MOF) post-SCT: final results of a multi-center, randomized, dose-finding trial. ASH Annual Meeting Abstracts. Blood. 2006;108:43
  21. Attal M, Huguet F, Rubie H, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood. 1992;79:2834–2840
  22. Rosenthal J, Sender L, Secola R, et al. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant. 1996;18:185–191
  23. Simon M, Hahn T, Ford LA, et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant. 2001;27:627–633
  24. Ohashi K, Tanabe J, Watanabe R, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol. 2000;64:32–38
  25. Essell JH, Thompson JM, Harman GS, et al. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1992;10:367–372
  26. Marsa-Vila L, Gorin NC, Laporte JP, et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol. 1991;47:346–354
  27. Hagglund H, Ringden O, Remberger M, et al. Risk factors for hepatic veno-occlusive disease in 500 allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 1997;19(Suppl 1):S17
  28. Park YD, Yasui M, Yoshimoto T, et al. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant. 1997;19:915–920
  29. Hagglund H, Remberger M, Klaesson S, et al. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood. 1998;92:4568–4572
  30. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100:1977–1983
  31. Gardner M, Altman DG. Statistics With Confidence. Tavistock Square, London, UK: Wiley Blackwell; 1989;6–27
  32. Armitage P, Berry G. Statistical Methods in Medical Research. Oxford, UK: Oxford Blackwell; 1987;117–120
  33. Copelan EA, Penza SL, Theil KS, et al. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy. Bone Marrow Transplant. 2000;26:1037–1043
  34. Lee JH, Lee KH, Kim S, et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. Br J Haematol. 2002;118:1087–1094
  35. Lee KH, Lee JH, Choi SJ, et al. Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;24:591–599
  36. Radich JP, Sanders JE, Buckner CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total body irradiation–containing regimens. J Clin Oncol. 1993;11:304–313
  37. Lapierre V, Mahe C, Auperin A, et al. Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. Transplantation. 2005;80:314–319
  38. Bouligand J, Le Maitre A, Valteau-Couanet D, et al. Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors. Clin Pharmacol Ther. 2007;82:402–409
  39. Horn B, Reiss U, Matthay K, et al. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma. Bone Marrow Transplant. 2002;29:409–415
  40. Lee JL, Gooley T, Bensinger W, et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 1999;5:306–315
  41. Meresse V, Hartmann O, Vassal G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan–containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant. 1992;10:135–141
  42. Baxter-Lowe LA. Molecular techniques for typing unrelated marrow donors: potential impact of molecular typing disparity on donor selection. Bone Marrow Transplant. 1994;14(Suppl 4):S42–S50
  43. Crilley P, Topolsky D, Styler MJ, et al. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. Bone Marrow Transplant. 1995;15:361–365
  44. Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:949–954
  45. Holland HK, Dix SP, Geller RB, et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem cell transplantation and comprehensive supportive care. J Clin Oncol. 1996;14:1156–1164
  46. Vassal G, Koscielny S, Challine D, et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1996;37:247–253
  47. Carreras E, Viguria MC, Rovira M, et al. Veno-occlusive disease of the liver after allogeneic blood and marrow transplantation: a retrospective analysis of 376 consecutive BMT performed at a single centre. Bone Marrow Transplant. 1998;21(Suppl 1):S239
  48. Jillella AP, Doria R, Khan K, et al. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplant. 1999;23:1095–1100
  49. Rocha E, Viguria MC, Montes R, et al. Plasma levels of t-PA Ag and D-dimer predict development of veno-occlusive disease of the liver (VOD) in patients undergoing allogeneic stem cell transplant. Blood. 2001;98:3541
  50. Parikh CR, McSweeney PA, Korular D, et al. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int. 2002;62:566–573
  51. Schetelig J, Kroger N, Held TK, et al. Allogeneic transplantation after reduced conditioning in high-risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica. 2002;87:299–305
  52. Einsele H, Bamberg M, Budach W, et al. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplant. 2003;32:593–599
  53. Hahn T, Rondeau C, Shaukat A, et al. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant. 2003;32:405–410
  54. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857–864
  55. Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic veno-occlusive disease in bone marrow transplantation. Blood. 2004;104:1574–1577
  56. Styler MJ, Crilley P, Biggs J, et al. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis. Bone Marrow Transplant. 1996;18:171–176
  57. Hasegawa S, Horibe K, Kawabe T, et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Bone Marrow Transplant. 1998;22:1191–1197
  58. Sullivan KM, Kansu E, Storer B, et al. Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation. Biol Blood Marrow Transplant. 1998;4:20–26
  59. Locasciulli A, Testa M, Valsecchi MG, et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation. 1999;68:1486–1491
  60. Copelan EA, Penza SL, Pohlman B, et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2000;25:1243–1248
  61. Tomas JF, Sanz-Rodriguez C, de Soria VG, et al. Plasma endothelin-1 levels after stem cell transplantation. Bone Marrow Transplant. 2000;26:1199–1204
  62. Moscardo F, Sanz GF, de La Rubia J, et al. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection. Bone Marrow Transplant. 2001;27:983–988
  63. Park SH, Lee MH, Lee H, et al. A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:137–143
  64. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101:2043–2048
  65. Moscardo F, Urbano-Ispizua A, Sanz GF, et al. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol. 2003;31:545–550
  66. Kalayoglu-Besisik S, Yenerel MN, Caliskan Y, et al. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years. Transplant Proc. 2005;37:2285–2289
  67. Cesaro S, Pillon M, Talenti E, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica. 2005;90:1396–1404
  68. Lee JH, Choi SJ, Kim SE, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol. 2005;84:321–330
  69. Sartori MT, Spiezia L, Cesaro S, et al. Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population. Thromb Hemost. 2005;93:682–689
  70. Batsis I, Yannaki E, Kaloyannidis P, et al. Veno-occlusive disease prophylaxis with fresh-frozen plasma and heparin in bone marrow transplantation. Thromb Res. 2006;118:611–618
  71. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578–1582
  72. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic veno-occlusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002;8:493–500
  73. Litzow MR, Repoussis PD, Schroeder G, et al. Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator. Leuk Lymphoma. 2002;43:2099–2107
  74. Bajwa RP, Cant AJ, Abinun M, et al. Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment. Bone Marrow Transplant. 2003;31:591–597
  75. Sucak GT, Aki ZS, Yagci M, et al. Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience. Transplant Proc. 2007;39:1558–1563
  76. Haussmann U, Fischer J, Eber S, et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica. 2006;91:795–800
  77. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337–4343
  78. Song JS, Seo JJ, Moon HN, et al. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children. J Korean Med Sci. 2006;21:897–903
  79. Brice K, Valerie B, Claire G, et al. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics. Pharmacoepidemiol Drug Saf. 2007;17:135–143
  80. Cheuk DK, Wang P, Lee TL, et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40:935–944
  81. Blostein MD, Paltiel OB, Thibault A, et al. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant. 1992;10:439–443
  82. Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002;8:145–154
  83. Barker CC, Anderson RA, Sauve RS, et al. GI complications in pediatric patients post-BMT. Bone Marrow Transplant. 2005;36:51–58
  84. Barker CC, Butzner JD, Anderson RA, et al. Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2003;32:79–87
  85. Richardson P, Soiffer R, Antin JH, et al. Defibrotide (DF) for the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post-SCT: final results of a phase II, multicenter, randomized study and preliminary analyses of surrogate markers and ultrasound findings. Blood. 2004;104
  86. Richardson P, Soiffer RJ, Antin JH, et al. Defibrotide (DF) for the treatment of veno-occlusive disease (VOD) and multi-system organ failure (MOF) post-SCT: analysis of response and survival according to degree and type of MOF. Blood. 2005;106:399
  87. Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In:  Thomas ED,  Blume KG,  Forman SJ editor. Hemopoietic Cell Transplantation. Malden, MA: Blackwell; 1999;p. 627–658
  88. Aversa F, Terenzi A, Felicini R, et al. Haploidentical stem cell transplantation for acute leukemia. Int J Hematol. 2002;76(Suppl 1):165–168
  89. Olavarria E, Kanfer E, Szydlo R, et al. High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience. Br J Haematol. 2000;108:769–777
  90. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8:468–476
  91. Ramasamy K, Lim ZY, Pagliuca A, et al. Incidence and management of hepatic veno-occlusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2006;38:823–824
  92. Olavarria E, Hassan M, Eades A, et al. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia. 2000;14:1954–1959
  93. Clopes A, Sureda A, Sierra J, et al. Absence of veno-occlusive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage. Eur J Haematol. 2006;77:1–6
  94. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus–associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008;14:59–66
  95. Soiffer RJ, Dear K, Rabinowe SN, et al. Hepatic dysfunction following T-cell–depleted allogeneic bone marrow transplantation. Transplantation. 1991;52:1014–1019
  96. Girinsky T, Benhamou E, Bourhis JH, et al. Prospective randomized comparison of single-dose versus hyperfractionated total body irradiation in patients with hematologic malignancies. J Clin Oncol. 2000;18:981–986
  97. Cosset JM, Baume D, Pico JL, et al. Single-dose versus hyperfractionated total body irradiation before allogeneic bone marrow transplantation: a non-randomized comparative study of 54 patients at the Institut Gustave-Roussy. Radiother Oncol. 1989;15:151–160
  98. Locasciulli A, Bacigalupo A, Alberti A, et al. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation. 1989;48:68–72
  99. Ayash LJ, Hunt M, Antman K, et al. Hepatic veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol. 1990;8:1699–1706
  100. Resbeut M, Altschuler C, Blaise D, et al. Results of fractionated TBI prior to bone marrow transplantation in standard-risk leukaemia at Marseille. Radiother Oncol. 1990;18(Suppl 1):132–134
  101. Atkinson K, Biggs J, Noble G, et al. Preparative regimens for marrow transplantation containing busulfan are associated with hemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis. Bone Marrow Transplant. 1987;2:385–394
  102. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011–1016
  103. Morgan M, Dodds A, Atkinson K, et al. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol. 1991;77:529–534
  104. Petersdorf EW. HLA matching in allogeneic stem cell transplantation. Curr Opin Hematol. 2004;11:386–391
  105. Bartelink IH, Bredius RG, Ververs TT, et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:88–98
  106. Nabhan C, Mehta J, Tallman MS. The role of bone marrow transplantation in acute promyelocytic leukemia. Bone Marrow Transplant. 2001;28:219–226
  107. Goldman JM, Marin D, Olavarria E, et al. Clinical decisions for chronic myeloid leukemia in the imatinib era. Semin Hematol. 2003;40:98–103
  108. Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112:4425–4431
  109. Platzbecker U, von Bonin M, Goekkurt E, et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant. 2009;15:101–108
  110. Richardson P, Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol. 2001;106:57–68
  111. Mahmoud HK. Schistosomiasis as a predisposing factor to veno-occlusive disease of the liver following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996;17:401–403
  112. Bearman SI, Lee JL, Baron AE, et al. Treatment of hepatic veno-occlusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood. 1997;89:1501–1506
  113. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000;111:1122–1129
  114. Brugieres L, Hartmann O, Benhamou E, et al. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome. Bone Marrow Transplant. 1988;3:53–58
  115. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737–744
  116. Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicenter study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant. 2004;33:189–195
  117. Gordon B, Tarantolo S, Ruby E, et al. Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 1998;22:999–1003
  118. Haire WD. Multiple organ dysfunction syndrome in hematopoietic stem cell transplantation. Crit Care Med. 2002;30:S257–S262
  119. Haire WD. The multiple organ dysfunction syndrome in cancer patients undergoing hematopoietic stem cell transplantation. Semin Thromb Hemost. 1999;25:223–237
  120. Haire WD, Ruby EI, Gordon BG, et al. Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA. 1995;274:1289–1295
  121. Khassawneh BY, White P, Anaissie EJ, et al. Outcome from mechanical ventilation after autologous peripheral blood stem cell transplantation. Chest. 2002;121:185–188
  122. Diaz de Heredia C, Moreno A, Olive T, et al. Role of the intensive care unit in children undergoing bone marrow transplantation with life-threatening complications. Bone Marrow Transplant. 1999;24:163–168
  123. Rossi R, Shemie SD, Calderwood S. Prognosis of pediatric bone marrow transplant recipients requiring mechanical ventilation. Crit Care Med. 1999;27:1181–1186
  124. Haire WD, Ruby EI, Stephens LC, et al. A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 1998;4:142–150
  125. Morris JD, Harris RE, Hashmi R, et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant. 1997;20:871–878
  126. Rubenfeld GD, Crawford SW. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med. 1996;125:625–633
  127. Afessa B, Tefferi A, Hoagland HC, et al. Outcome of recipients of bone marrow transplants who require intensive care unit support. Mayo Clin Proc. 1992;67:117–122
  128. Letourneau I, Dorval M, Belanger R, et al. Acute renal failure in bone marrow transplant patients admitted to the intensive care unit. Nephron. 2002;90:408–412
  129. Keenan HT, Bratton SL, Martin LD, et al. Outcome of children who require mechanical ventilatory support after bone marrow transplantation. Crit Care Med. 2000;28:830–835
  130. Zager RA, O'Quigley J, Zager BK, et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis. 1989;13:210–216
  131. Lane PH, Mauer SM, Blazar BR, et al. Outcome of dialysis for acute renal failure in pediatric bone marrow transplant patients. Bone Marrow Transplant. 1994;13:613–617
  132. Kist-van Holthe JE, van Zwet JM, Brand R, et al. Bone marrow transplantation in children: consequences for renal function shortly after and 1 year post-BMT. Bone Marrow Transplant. 1998;22:559–564
  133. Gruss E, Bernis C, Tomas JF, et al. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol. 1995;15:473–479
  134. Wingard JR, Mellits ED, Jones RJ, et al. Association of hepatic veno-occlusive disease with interstitial pneumonitis in bone marrow transplant recipients. Bone Marrow Transplant. 1989;4:685–689
  135. Merouani A, Shpall EJ, Jones RB, et al. Renal function in high-dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int. 1996;50:1026–1031
  136. Kist-van Holthe JE, Goedvolk CA, Brand R, et al. Prospective study of renal insufficiency after bone marrow transplantation. Pediatr Nephrol. 2002;17:1032–1037
  137. Torrecilla C, Cortes JL, Chamorro C, et al. Prognostic assessment of the acute complications of bone marrow transplantation requiring intensive therapy. Intens Care Med. 1988;14:393–398
  138. Todd K, Wiley F, Landaw E, et al. Survival outcome among 54 intubated pediatric bone marrow transplant patients. Crit Care Med. 1994;22:171–176
  139. Jacobe SJ, Hassan A, Veys P, et al. Outcome of children requiring admission to an intensive care unit after bone marrow transplantation. Crit Care Med. 2003;31:1299–1305
  140. McDonald GB, Hinds MS, Fisher LB, et al. Liver toxicity following cytoreductive therapy for marrow transplantation: risk factors, incidence and outcome. Hepatology. 1991;14:162A
  141. Klaesson S, Ringden O, Ljungman P, et al. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?. Transplantation. 1995;60:1225–1230
  142. Gooley TA, Rajvanshi P, Schoch HG, et al. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology. 2005;41:345–352

 Financial disclosure: See Acknowledgments on page 164.

PII: S1083-8791(09)00418-2

doi: 10.1016/j.bbmt.2009.08.024

Biology of Blood and Marrow Transplantation
Volume 16, Issue 2 , Pages 157-168 , February 2010

Article Tools

* Image Usage & Resolution